西罗莫司片治疗什么病？

(Leipaming) What disease does it treat? Sirolimus tablets (rapamin) are approved for patients aged 13 or above who have received kidney transplants. At the same time, the drug has also been used in other solid organ transplants in clinical practice.

A study published abroad in 2011 showed that the renal function of recipients who switched to sirolimus tablets (rapamin) 3 months after kidney transplantation was better than that of recipients treated with CNI-based regimen 5 years after transplantation. Domestic research has also shown through prospective randomized controlled studies that sirolimus conversion therapy in patients with stable renal function in the early stage after kidney transplantation can significantly improve renal function, and no increase in acute rejection and other adverse events was found during the 2-year follow-up period.

Foreign studies have also found that for liver transplant patients with preoperative renal insufficiency, timely replacement of sirolimus tablets (rapamin) within 3 months after surgery can significantly improve renal function, while replacement after 1 year has no significant improvement in renal function. In lung transplantation, low-dose CNI combined with sirolimus can improve creatinine clearance in lung transplant recipients.

In a domestic study, one patient with LAM used sirolimus tablets (rapamin) before surgery, but was switched back to sirolimus tablets (rapamin) after surgery due to chylothorax. The patient's pleural effusion was significantly reduced after the switch. There are also reports in the literature that sirolimus still has a good therapeutic effect when LAM recurs after lung transplantation. It should be noted that sirolimus tablets (rapamin) have anti-proliferative effects. Previous literature has reported that the anti-rejection reaction of sirolimus immediately after lung transplantation led to incision dehiscence and severe airway complications, eventually leading to the death of the patient. This LAM patient stopped taking sirolimus tablets (rapamin) 2 months before lung transplantation, and there was no anastomosis or poor wound healing after surgery. In addition, one patient was switched back to tacrolimus treatment due to pneumothorax, because sirolimus tablets (rapamin) affected tissue growth and healing. In addition, the time for domestic study patients to switch to sirolimus tablets (rapamin) ranged from 2 to 18 months after surgery, and all patients were switched to medication after the bronchial anastomosis was confirmed to be healed under a bronchoscope.

The above are the indications of sirolimus tablets (rapamin) provided by our medical companions and the effects of its clinical trials. It can be seen that the effect of (rapamin) in treating kidney transplantation is still very good.

Recommended related hot articles: /newsDetail/76782.html